PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer

Published:2024-07-20 Issue:21 Volume:42 Page:2616-2617
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Mo Dun-Chang¹^ORCID,Chen Long¹,Wu Yu¹,Huang Jian-Feng¹,Liang Xiu-Juan¹

Affiliation:

1. Dun-Chang Mo, MD, Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China; Long Chen, MD, Otorhinolaryngology Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China; Yu Wu, MD, Medical Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China; and Jian-Feng Huang, MD and Xiu-Juan Liang, MD, Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.24.00230

Reference4 articles.

1. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

2. A case of discordant histology and expression of programmed death ligand 1 between primary tumor and brain metastases in adenosquamous carcinoma of the lung

3. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

4. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to D.-C. Mo et al;Journal of Clinical Oncology;2024-07-20